Background {#S0001}
==========

Patient-reported outcomes (PROs) in rheumatoid arthritis (RA) are used both in clinical trials[@CIT0001] and in clinical practice.[@CIT0002] In trials, clinical improvements have been shown to correlate with concurrent improvements in various PROs.[@CIT0003]--[@CIT0008] However, less is known about clinical responses as predictors of PRO changes.

Since patients' subjective assessment is an important factor in RA management, including treatment adherence[@CIT0009] and disease remission,[@CIT0010],[@CIT0011] it is important to understand what kind of PRO response can be expected from a certain level of clinical response. In addition, it is of interest to assess predictive relationship between clinical and PRO improvements within a relatively short time: patients are keen to experience improvements as soon as possible, and 6 months are usually considered the maximum time for changing therapies that patients consider to be ineffective.

In a randomized, open-label trial in Latin American patients with moderate-to-severe RA and an inadequate response to methotrexate (MTX) (NCT00848354), adding etanercept (ETN) to MTX was more effective than adding another conventional disease-modifying anti-rheumatic drug (DMARD), for both clinical outcomes and PROs.[@CIT0012],[@CIT0013] In this post hoc analysis, we used data from that trial to examine whether changes from baseline in clinical outcomes at week 12 were predictive of PRO changes at week 24.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

All study participants provided written informed consent. In addition, institutional approval was obtained from each center in which the study was conducted (see [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=228866.zip)]{.ul}). Details of the 24-week, randomized phase of that study were published previously.[@CIT0013] Briefly, patients from Argentina, Chile, Colombia, Mexico, and Panama with moderate-to-severe RA and an inadequate response to MTX were randomized to receive open-label ETN 50 mg/week plus MTX (n=281) or an additional conventional DMARD (hydroxychloroquine or sulfasalazine) plus MTX (n=142) for 24 weeks. Main inclusion criterion was active RA despite MTX monotherapy (≥7.5 and ≤25 mg/week) for at least 3 months, as indicated by ≥6 swollen joints, ≥8 tender joints, and erythrocyte sedimentation rate of ≥28 mm/hr. Main exclusion criteria were previous treatment with ETN or other biologics, treatment with a concurrent DMARD (other than MTX) within 3 months from baseline, and treatment with \>1 NSAID at screening. Clinical endpoints were assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24, and included the proportions of patients who achieved the American College of Rheumatology (ACR) improvement criteria (ACR20, ACR50, and ACR70) and the 28-joint Disease Activity Scores (DAS28) consistent with remission (\<2.6) and low disease activity (\<3.2). The 24-week PROs included Health Assessment Questionnaire Disability Index (HAQ-DI), 36-item Short Form, Physical Component Summary (SF-36 PCS), Hospital Anxiety and Depression Scale subscales for anxiety (HADS-A) and depression (HADS-D), Physician and Patient Global Assessment scores (PGA, PtGA), Physician and Patient Satisfaction, Work Productivity and Activity Impairment: RA (WPAI:RA), and resource utilization.

Data Analysis {#S0002-S2002}
-------------

Baseline-to-week-24 PRO changes were calculated by week-12 responses on the ACR (\<20, ≥20 to \<50, ≥50 to \<70, and ≥70) and on the DAS28 (≥3.2, ≥2.6 to \<3.2, and \<2.6). Observed-cases data for ETN+MTX and DMARD+MTX groups were analyzed using ANCOVA with linear contrast, adjusted for baseline PRO and ACR/DAS28 values.

Results {#S0003}
=======

Baseline Characteristics {#S0003-S2001}
------------------------

Baseline characteristics were published previously.[@CIT0013] Most of the 423 randomized patients were women (376; 89%); the average disease duration was 8.3 years ([Table 1](#T0001){ref-type="table"}).Table 1Baseline CharacteristicsETN + MTX\
n = 281DMARD + MTX\
n = 142Age, years, mean ± SD48 ± 1249 ± 11Women, n (%)248 (88)128 (90)Race, n (%)White134 (48)65 (46)Mestizo60 (21)34 (24)African-Latin American39 (14)23 (16)Other48 (17)20 (14)Disease duration, years, mean ± SD8 ± 79 ± 8Rheumatoid factor-positive, n (%)242 (86)119 (84)ESR, mm/hr, mean ± SD43 ± 1743 ± 16DAS28, mean ± SD6.6 ± 0.76.7 ± 0.7HAQ Total Score, mean ± SD1.6 ± 0.71.6 ± 0.7SF-36 PCS, mean ± SD30.2 ± 7.230.1 ± 6.9HADS-Anxiety, mean ± SD8.9 ± 4.59.2 ± 4.8HADS-Depression, mean ± SD8.0 ± 3.97.9 ± 4.0PGA, mean ± SD6.7 ± 1.66.7 ± 1.6PtGA, mean ± SD7.1 ± 2.07.1 ± 1.9[^1]

Disability and Physical Component-Related Quality of Life {#S0003-S2002}
---------------------------------------------------------

There was a significant linear trend for improvement in HAQ-DI and SF-36 PCS at week 24 with an increasing level of ACR response or reduction in DAS28 scores at week 12, regardless of the choice of add-on treatment ([Figure 1](#F0001){ref-type="fig"}). Consistent with the published, prospectively defined analyses,[@CIT0013] the PRO improvement generally favored ETN over DMARD.Figure 1(**A**--**D**) Relationship between HAQ-DI and SF-36 PCS and clinical response.**Notes:** Numerals in each column denote the numbers of participants. *P*-values are from ANCOVA linear trend contrast within each treatment.**Abbreviations:** ACR, American College of Rheumatology (response criteria); ANCOVA, analysis of covariance; CI, confidence interval; DAS28, 28-joint Disease Activity Scale (response criteria); DMARD, disease-modifying anti-rheumatic drug; ETN, etanercept; HAQ-DI, Health Assessment Questionnaire Disability Index; SF-36 PCS, Short Form 36, Physical Component Summary.

Anxiety and Depression {#S0003-S2003}
----------------------

Overall, patients with a greater ACR or DAS28 response at week 12 also tended to experience a greater reduction in anxiety or depression at week 24, with the linear trends being significant for most depresion-related assessments ([Figure 2](#F0002){ref-type="fig"}C-D). There was no significant linear trend in anxiety improvement by DAS28 response for any treatment ([Figure 2B](#F0002){ref-type="fig"}).Figure 2(**A**--**D**) Relationship between HADS subscales and clinical response.**Notes:** Numerals in each column denote the numbers of participants. *P*-values are from ANCOVA linear trend contrast within each treatment.**Abbreviations:** ACR, American College of Rheumatology (response criteria); ANCOVA, analysis of covariance; CI, confidence interval; DAS28, 28-joint Disease Activity Scale (response criteria); DMARD, disease-modifying anti-rheumatic drug; ETN, etanercept; HADS-A, Hospital Anxiety and Depression Scales subscale for anxiety; HADS-A, Hospital Anxiety and Depression Scales subscale for anxiety.

Global Assessments and Treatment Satisfaction {#S0003-S2004}
---------------------------------------------

At week 24, there was an overall significant linear trend for improvement in patients' global assessment (PGA or PtGA) with an increasing level of week-12 clinical response, regardless of the add-on treatment (ETN or DMARD) ([Figure 3](#F0003){ref-type="fig"}). The PRO improvement generally favored ETN over DMARD, consistent with protocol-specified analyses.[@CIT0013] Similar observations were made for patients' and physicians' satisfaction with treatment ([Figure 4](#F0004){ref-type="fig"}).Figure 3(**A**--**D**) Relationship between PGA/PtGA and clinical response.**Notes:** Numerals in each column denote the numbers of participants. *P*-values are from ANCOVA linear trend contrast within each treatment.**Abbreviations:** ACR, American College of Rheumatology (response criteria); ANCOVA, analysis of covariance; CI, confidence interval; DAS28, 28-joint Disease Activity Scale (response criteria); DMARD, disease-modifying anti-rheumatic drug; ETN, etanercept; PGA, Physician Global Assessment; PtGA, Patient Global Assessment.Figure 4(**A**--**D**) Satisfaction with treatment and clinical response.**Note:** Numerals in each column denote the numbers of participants. *P*-values are from ANCOVA linear trend contrast within each treatment.**Abbreviations:** ACR, American College of Rheumatology (response criteria); ANCOVA, analysis of covariance; CI, confidence interval; DAS28, 28-joint Disease Activity Scale (response criteria); DMARD, disease-modifying anti-rheumatic drug; ETN, etanercept; PGA, Physician Global Assessment; PtGA, Patient Global Assessment.

WPAI and Resource Utilization {#S0003-S2005}
-----------------------------

There were significant linear trends for improvement in WPAI:RA subscales by ACR or DAS28 response for ETN treatment, but a low number of patients with available data precluded trend analysis for the DMARD group ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=228866.zip)]{.ul}). The week-24 linear trends were less clear in regard to resource utilization: the trends were significant for ETN-treated patients in terms of reduced visits to rheumatologists, other physicians, or RA-related emergency room visits by ACR, but not by DAS28 response, but there were no significant trends for DMARD treatment ([[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=228866.zip)]{.ul}).

Discussion {#S0004}
==========

These data suggest that, in patients with moderate-to-severe RA and an inadequate response to MTX, PRO improvement at week 24 was proportional to clinical response at week 12. To the best of our knowledge, this is the first study that evaluated clinical outcomes as predictors of PRO response in RA. Since the treatment groups were similar in terms of baseline characteristics, and since our statistical model was adjusted for baseline PRO and ACR/DAS28 values, the significant linear trends observed are not likely to be baseline-related artifacts.

The fact that significant linear trends in PRO improvement were associated with 2 measures of clinical improvement supports the robustness of our findings. In addition, for certain PROs, significant linear trends were observed in both ETN+MTX- and DMARD+MTX-treated patients, which suggests a predictive relationship independent of the type of treatment or the novelty factor (biologic vs. conventional DMARD). In general, improvements in ETN-treated patients exceeded those in patients receiving DMARD, which is consistent with the prespecified analyses of these data,[@CIT0013] but a trend of greater PRO improvements in patients who had experienced a greater clinical response was observed in both treatment groups.

Limitations of this analysis include its post hoc nature; an open-label design, which typically limits interpretation of PRO data (patients or physicians may be more inclined to be satisfied with a novel treatment); a small number of patients available for certain outcomes (most notably WPAI:RA subscales); and the fact that PtGA is a component of DAS28,[@CIT0014] so the significant linear trend observed for PtGA by DAS28 response was not surprising.

Conclusions {#S0005}
===========

In conclusion, clinical improvements could serve as predictors of certain future PRO improvements, which may be of use in clinical practice, particularly in setting treatment expectations. These findings would need to be corroborated in prospectively designed studies.
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[^1]: **Note:** Data from Machado et al.[@CIT0013]

    **Abbreviations:** DAS28, 28-joint Disease Activity Scale; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Assessment Questionnaire; MTX, methotrexate; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; SD, standard deviation; SF-36 PCS, Short Form-36, Physical Component Summary.
